Pharvaris (NASDAQ:PHVS) Price Target Raised to $62.00

Pharvaris (NASDAQ:PHVS) had its price objective increased by Royal Bank Of Canada from $52.00 to $62.00 in a research note issued to investors on Wednesday, MarketBeat reports. The firm currently has an outperform rating on the stock.

A number of other brokerages have also recently commented on PHVS. Morgan Stanley raised their price target on shares of Pharvaris from $46.00 to $62.00 and gave the stock an “overweight” rating in a research note on Wednesday. Citizens Jmp raised their target price on Pharvaris from $75.00 to $79.00 and gave the stock a “market outperform” rating in a research report on Wednesday. UBS Group set a $79.00 price target on Pharvaris in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Finally, Wedbush restated an “outperform” rating and issued a $42.00 target price on shares of Pharvaris in a research note on Tuesday. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $59.50.

Pharvaris Price Performance

PHVS opened at $38.02 on Wednesday. The company has a market capitalization of $2.49 billion, a P/E ratio of -12.47 and a beta of -2.33. The firm’s fifty day moving average price is $35.09 and its two-hundred day moving average price is $31.38. Pharvaris has a fifty-two week low of $20.65 and a fifty-two week high of $43.25.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). On average, equities research analysts expect that Pharvaris will post -3.12 EPS for the current fiscal year.

Insider Transactions at Pharvaris

In other news, Director Robert Glassman sold 8,000 shares of Pharvaris stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $37.55, for a total value of $300,400.00. Following the completion of the sale, the director directly owned 10,500 shares of the company’s stock, valued at approximately $394,275. This trade represents a 43.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President Peng Lu sold 15,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $40.68, for a total value of $610,200.00. Following the sale, the president owned 65,179 shares of the company’s stock, valued at approximately $2,651,481.72. The trade was a 18.71% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 141,655 shares of company stock worth $5,098,602. Corporate insiders own 11.84% of the company’s stock.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. Engineers Gate Manager LP bought a new stake in Pharvaris during the 2nd quarter worth about $1,143,000. Amundi lifted its position in Pharvaris by 61.4% during the 2nd quarter. Amundi now owns 49,944 shares of the company’s stock valued at $1,727,000 after purchasing an additional 18,992 shares during the period. California State Teachers Retirement System boosted its stake in shares of Pharvaris by 3,210.1% in the 2nd quarter. California State Teachers Retirement System now owns 799,490 shares of the company’s stock valued at $27,646,000 after purchasing an additional 775,337 shares during the last quarter. Moore Capital Management LP bought a new position in shares of Pharvaris in the 2nd quarter valued at about $1,522,000. Finally, Alyeska Investment Group L.P. grew its position in shares of Pharvaris by 225.5% during the 2nd quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company’s stock worth $14,068,000 after buying an additional 281,829 shares during the period.

Pharvaris News Roundup

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris reported that once-daily extended-release deucrictibant reduced HAE attack rates by 83% versus placebo in the Phase 3 CHAPTER-3 trial. The result was statistically significant, with a p-value below 0.0001, and the study met its primary and secondary efficacy endpoints. The company plans to begin regulatory submissions in the first half of 2027. Pharvaris CHAPTER-3 topline data
• Positive Sentiment: The results strengthen Pharvaris’ potential to offer convenient oral treatments for both HAE prevention and acute attacks. Analysts believe the data could help the company gain market share in the HAE market. Pharvaris HAE market-share analysis
• Positive Sentiment: Analyst sentiment remains broadly favorable. Leerink Partners reiterated a Buy/Outperform view, while RBC Capital raised its price target to $62, Citizens JMP increased its target to $79, and HC Wainwright maintained a Buy rating with a $60 target. These revisions imply substantial upside from recent trading levels.
• Neutral Sentiment: Pharvaris is still a clinical-stage biotechnology company. Regulatory approval, launch execution, competition from established HAE therapies and continued cash requirements remain key risks. The company also recently reported a quarterly loss that was larger than analysts expected.
• Negative Sentiment: Director Robert Glassman sold 8,000 shares for approximately $300,400, reducing his direct holdings by 43.24%. President Peng Lu also sold 15,000 shares worth about $610,200, cutting his ownership by 18.71%. The insider selling may create a modest sentiment overhang, although it does not alter the favorable clinical results.

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.